JO3183B1 - طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 - Google Patents

طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Info

Publication number
JO3183B1
JO3183B1 JOP/2011/0021A JOP20110021A JO3183B1 JO 3183 B1 JO3183 B1 JO 3183B1 JO P20110021 A JOP20110021 A JO P20110021A JO 3183 B1 JO3183 B1 JO 3183B1
Authority
JO
Jordan
Prior art keywords
dii4
methods
diseases
disorders
disease
Prior art date
Application number
JOP/2011/0021A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3183B1 publication Critical patent/JO3183B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي أساليب لعلاج مرض أو اضطراب، تكون فيه الزيادة في عدد خلايا (تريغ) T التنظيمية مفيدا، عن طريق إعطاء جرعة دوائية لمستهدف يعاني من ذلك المرض أو الاضطراب بجرعة علاجية من ضاد DII4 التي تقيد مسارات إشارة ثلمة-DII4، بذلك يزداد عدد خلايا تريغ. تشمل الأمراض أو الاضطرابات القابلة للعلاج عن طريق أساليب من هذا الاختراع مثل التصلب المتعدد (MS)، داء السكري، وما شابهها. يشمل الضاد المناسب DII4 لهذا الاختراع الأجسام المضادة أو جزيئات من الأجسام المضادة التي تربط بشكل خاص DII4 وتقيد تفاعلات ثلمة-DII4، والمجال الخارجي من DII4، وما شابهها. يوفر الاختراع أيضا أساليب لمنع حدوث أو عودة حدوث هكذا أمراض أو اضطرابات في مستهدف تعرض سابقا أو لديه قابلية للتعرض أو تطوير هكذا أمراض أو اضطرابات. علاوة على ذلك، فإن الأساليب من هذا الاختراع تكون مفيدة لمنع أو لعلاج رفض زراعة الأعضاء أو داء الطعم حيال الثوى.
JOP/2011/0021A 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 JO3183B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
JO3183B1 true JO3183B1 (ar) 2018-03-08

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Country Status (29)

Country Link
US (3) US8889133B2 (ar)
EP (2) EP2528945B1 (ar)
JP (2) JP5883801B2 (ar)
KR (2) KR101832118B1 (ar)
CN (2) CN102884081A (ar)
AR (1) AR080026A1 (ar)
AU (2) AU2011210773B2 (ar)
BR (2) BR112012018766A2 (ar)
CA (2) CA2787394C (ar)
CY (2) CY1118223T1 (ar)
DK (2) DK2528945T3 (ar)
ES (2) ES2609663T3 (ar)
HR (2) HRP20170249T1 (ar)
HU (2) HUE031432T2 (ar)
IL (2) IL220887A (ar)
JO (2) JO3183B1 (ar)
LT (2) LT2528945T (ar)
MX (2) MX343553B (ar)
MY (2) MY156538A (ar)
PL (2) PL2528945T3 (ar)
PT (2) PT2528945T (ar)
RS (2) RS55595B1 (ar)
RU (2) RU2587620C2 (ar)
SG (4) SG182528A1 (ar)
SI (2) SI2528945T1 (ar)
SM (3) SMT201700021T1 (ar)
TW (2) TWI564019B (ar)
UY (1) UY33206A (ar)
WO (2) WO2011094467A2 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2470568A2 (en) 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
RU2648154C2 (ru) 2013-07-09 2018-03-22 Аблбио Новые белки, специфично связывающиеся с двумя мишенями -dll4 и vegf-, и их применение
JP6560200B2 (ja) * 2013-10-17 2019-08-14 ザ ジェネラル ホスピタル コーポレイション 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
WO2015154795A1 (en) * 2014-04-08 2015-10-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Combination therapy for the treatment of autoimmune diseases
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
EP3886856A4 (en) * 2018-11-29 2022-01-19 Zucco Sassi Yonezawa Siviglia, Debora METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER
WO2022210802A1 (ja) * 2021-03-30 2022-10-06 国立大学法人熊本大学 筋萎縮症治療剤
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
NZ568739A (en) 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
CA2654304A1 (en) 2006-06-06 2007-12-13 Genentech, Inc. Compositions and methods for modulating vascular development
CN101500605B (zh) 2006-08-07 2014-04-30 瑞泽恩制药公司 Dll4拮抗剂在治疗局部缺血性损伤中的用途
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2470568A2 (en) * 2009-08-29 2012-07-04 Abbott Laboratories Therapeutic dll4 binding proteins
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
SG182528A1 (en) 2012-08-30
HUE031432T2 (en) 2017-07-28
CY1118551T1 (el) 2017-07-12
DK2528945T3 (en) 2017-02-06
TW201136601A (en) 2011-11-01
TWI600433B (zh) 2017-10-01
RU2587620C2 (ru) 2016-06-20
BR112012018820A2 (pt) 2017-01-10
US20110189176A1 (en) 2011-08-04
SG10201500404QA (en) 2015-03-30
MX343555B (es) 2016-11-10
AU2011210773B2 (en) 2015-11-19
LT2528946T (lt) 2017-01-25
JP5883801B2 (ja) 2016-03-15
SMT201600412B (it) 2017-01-10
US8889133B2 (en) 2014-11-18
RU2587624C2 (ru) 2016-06-20
WO2011094465A1 (en) 2011-08-04
IL220889A0 (en) 2012-09-24
CA2787615C (en) 2019-01-15
SI2528946T1 (sl) 2017-01-31
US20110189200A1 (en) 2011-08-04
MX2012008638A (es) 2012-12-05
RS55715B1 (sr) 2017-07-31
LT2528945T (lt) 2017-01-25
AR080026A1 (es) 2012-03-07
US8765125B2 (en) 2014-07-01
AU2011210773A1 (en) 2012-08-23
SI2528945T1 (sl) 2017-01-31
JO3242B1 (ar) 2018-03-08
CN102947336B (zh) 2015-12-02
RS55595B1 (sr) 2017-06-30
KR101797918B1 (ko) 2017-11-15
IL220889A (en) 2017-07-31
WO2011094467A3 (en) 2011-12-22
JP5997613B2 (ja) 2016-09-28
CA2787615A1 (en) 2011-08-04
AU2011210771B2 (en) 2015-12-10
CN102947336A (zh) 2013-02-27
PT2528945T (pt) 2016-12-14
PL2528946T3 (pl) 2017-04-28
KR20130008017A (ko) 2013-01-21
IL220887A (en) 2017-07-31
RU2012136817A (ru) 2014-03-10
CA2787394A1 (en) 2011-08-04
SMT201700021T1 (it) 2017-03-08
KR101832118B1 (ko) 2018-02-26
WO2011094465A4 (en) 2011-09-22
EP2528945B1 (en) 2016-10-26
ES2609663T3 (es) 2017-04-21
JP2013518122A (ja) 2013-05-20
CY1118223T1 (el) 2017-06-28
UY33206A (es) 2011-08-31
BR112012018820A8 (pt) 2018-03-13
CN102884081A (zh) 2013-01-16
EP2528946A1 (en) 2012-12-05
US20140255429A1 (en) 2014-09-11
MY156353A (en) 2016-02-15
HRP20170130T1 (hr) 2017-03-24
CA2787394C (en) 2019-01-08
KR20120123745A (ko) 2012-11-09
TW201615207A (zh) 2016-05-01
SMT201700021B (it) 2017-03-08
HRP20170249T1 (hr) 2017-04-07
MY156538A (en) 2016-02-26
SG182527A1 (en) 2012-08-30
HUE032985T2 (en) 2017-11-28
AU2011210771A1 (en) 2012-08-23
RU2012136816A (ru) 2014-03-10
WO2011094467A2 (en) 2011-08-04
MX2012008740A (es) 2012-08-31
DK2528946T3 (en) 2017-02-20
ES2605430T3 (es) 2017-03-14
EP2528946B1 (en) 2016-11-16
PL2528945T3 (pl) 2017-02-28
PT2528946T (pt) 2016-12-14
EP2528945A2 (en) 2012-12-05
JP2013518123A (ja) 2013-05-20
SG10201500416RA (en) 2015-04-29
BR112012018766A2 (pt) 2017-01-10
MX343553B (es) 2016-11-10
TWI564019B (zh) 2017-01-01

Similar Documents

Publication Publication Date Title
JO3183B1 (ar) طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
Sun et al. Macrophage phenotype in liver injury and repair
Jordan et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH
Walsh et al. Proteasome inhibitor-based therapy for antibody-mediated rejection
AU2017278220B2 (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
EA033400B1 (ru) Антитело против cd3 и его применение
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TW200716743A (en) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MY160892A (en) Antibodies to ccr2
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
NZ612175A (en) Anti ccr4 antibodies and uses thereof
Liu et al. Curcumin reduces brain-infiltrating T lymphocytes after intracerebral hemorrhage in mice
EA201500506A1 (ru) КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a
RU2014117952A (ru) Антитела против sema4a человека, используемые для лечения заболевания
EA202192488A1 (ru) Антитела против tsg-6 и их применения
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
PH12019500482A1 (en) Antibody for treating autoimmune diseases
Kikuchi et al. HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development
Wang et al. Cytokine Storm Induction Linked to Multi‐Organ Failure in Fatal Jellyfish Stings